Search

Your search keyword '"Nardozza, Anna Maria"' showing total 7 results
Start Over Author "Nardozza, Anna Maria"
7 results on '"Nardozza, Anna Maria"'

1. Characterization of a novel IDH2‐R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation

Author

Nardozza, Anna Maria, primary, Guarnera, Luca, additional, Travaglini, Serena, additional, Ottone, Tiziana, additional, Divona, Mariadomenica, additional, De Bellis, Eleonora, additional, Savi, Arianna, additional, Banella, Cristina, additional, Noguera, Nelida Ines, additional, Di Fusco, Davide, additional, Monteleone, Ivan, additional, and Voso, Maria Teresa, additional

Published
2023
Full Text
View/download PDF

2. Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells

Author

Travaglini, Serena, Angelini, Daniela Francesca, Alfonso, Valentina, Guerrera, Gisella, Lavorgna, Serena, Divona, Mariadomenica, Nardozza, Anna Maria, Consalvo, Maria Irno, Fabiani, Emiliano, De Bardi, Marco, Neri, Benedetta, Forghieri, Fabio, Marchesi, Francesco, Paterno, Giovangiacinto, Cerretti, Raffaella, Barragan, Eva, Fiori, Valentina, Dominici, Sabrina, Del Principe, Maria Ilaria, Venditti, Adriano, Battistini, Luca, Arcese, William, Lo-Coco, Francesco, Voso, Maria Teresa, and Ottone, Tiziana

Published
2020
Full Text
View/download PDF

3. Characterization of a novel IDH2‐R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.

Author

Nardozza, Anna Maria, Guarnera, Luca, Travaglini, Serena, Ottone, Tiziana, Divona, Mariadomenica, De Bellis, Eleonora, Savi, Arianna, Banella, Cristina, Noguera, Nelida Ines, Di Fusco, Davide, Monteleone, Ivan, and Voso, Maria Teresa

Subjects
*ACUTE myeloid leukemia, *CELL metabolism, *CELL differentiation, *GENETIC mutation, *KREBS cycle
Abstract

This article, published in the British Journal of Haematology, discusses a novel IDH2-R159H mutation found in a patient with acute myeloid leukaemia (AML). The mutation was acquired during disease progression and had a significant impact on cell metabolism and differentiation. The study also explores the sensitivity of the mutation to enasidenib, an oral inhibitor of mutant IDH2. The findings suggest that the presence of the IDH2-R159H mutation, along with another mutation, may be associated with a negative outcome and reduced response to enasidenib. The authors emphasize the importance of retesting for molecular changes during the course of the disease. [Extracted from the article]

Published
2024
Full Text
View/download PDF

4. Vitamin C Deficiency in Patients With Acute Myeloid Leukemia

Author

Ottone, Tiziana, primary, Faraoni, Isabella, additional, Fucci, Giorgio, additional, Divona, Mariadomenica, additional, Travaglini, Serena, additional, De Bellis, Eleonora, additional, Marchesi, Francesco, additional, Angelini, Daniela Francesca, additional, Palmieri, Raffaele, additional, Gurnari, Carmelo, additional, Giansanti, Manuela, additional, Nardozza, Anna Maria, additional, Montesano, Federica, additional, Fabiani, Emiliano, additional, Lindfors Rossi, Elisa Linnea, additional, Cerretti, Raffaella, additional, Cicconi, Laura, additional, De Bardi, Marco, additional, Catanoso, Maria Luisa, additional, Battistini, Luca, additional, Massoud, Renato, additional, Venditti, Adriano, additional, and Voso, Maria Teresa, additional

Published
2022
Full Text
View/download PDF

5. Mutational profile of ZBTB16‐RARA‐positive acute myeloid leukemia

Author

Fabiani, Emiliano, primary, Cicconi, Laura, additional, Nardozza, Anna Maria, additional, Cristiano, Antonio, additional, Rossi, Marianna, additional, Ottone, Tiziana, additional, Falconi, Giulia, additional, Divona, Mariadomenica, additional, Testi, Anna Maria, additional, Annibali, Ombretta, additional, Castelli, Roberto, additional, Lazarevic, Vladimir, additional, Rego, Eduardo, additional, Montesinos, Pau, additional, Esteve, Jordi, additional, Venditti, Adriano, additional, Della Porta, Matteo, additional, Arcese, William, additional, Lo‐Coco, Francesco, additional, and Voso, Maria Teresa, additional

Published
2021
Full Text
View/download PDF

6. Mutational Profile of Leukemic Stem Cells in FLT3-ITD Mutated AML

Author

Ottone, Tiziana, primary, Travaglini, Serena, additional, Alfonso, Valentina, additional, Angelini, Daniela, additional, Guerrera, Gisella, additional, Lavorgna, Serena, additional, Divona, Mariadomenica, additional, Nardozza, Anna Maria, additional, Cristiano, Antonio, additional, irno Consalvo, Maria, additional, de Bardi, Marco, additional, Neri, Benedetta, additional, Marchesi, Francesco, additional, Gurnari, Carmelo, additional, Paterno, Giovangiacinto, additional, Martini, Vincenza, additional, Battistini, Luca, additional, Venditti, Adriano, additional, Buccisano, Francesco, additional, Arcese, William, additional, Lo-Coco, Francesco, additional, and Voso, Maria Teresa, additional

Published
2019
Full Text
View/download PDF

7. Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells.

Author

Travaglini, Serena, Angelini, Daniela Francesca, Alfonso, Valentina, Guerrera, Gisella, Lavorgna, Serena, Divona, Mariadomenica, Nardozza, Anna Maria, Consalvo, Maria Irno, Fabiani, Emiliano, De Bardi, Marco, Neri, Benedetta, Forghieri, Fabio, Marchesi, Francesco, Paterno, Giovangiacinto, Cerretti, Raffaella, Barragan, Eva, Fiori, Valentina, Dominici, Sabrina, Del Principe, Maria Ilaria, and Venditti, Adriano

Subjects
ACUTE myeloid leukemia, GENETIC mutation, PROTEIN-tyrosine kinases, PROGENITOR cells, FLUORESCENCE
Abstract

Acute myeloid leukemia (AML) with FLT3-ITD mutations (FLT3-ITDmut) remains a therapeutic challenge, with a still high relapse rate, despite targeted treatment with tyrosine kinase inhibitors. In this disease, the CD34/CD123/CD25/CD99+ leukemic precursor cells (LPCs) phenotype predicts for FLT3-ITD-positivity. The aim of this study was to characterize the distribution of FLT3-ITD mutation in different progenitor cell subsets to shed light on the subclonal architecture of FLT3-ITDmut AML. Using high-speed cell sorting, we sequentially purified LPCs and CD34+ progenitors in samples from patients with FLT3-ITDmut AML (n = 12). A higher FLT3-ITDmut load was observed within CD34/CD123/CD25/CD99+ LPCs, as compared to CD34+ progenitors (CD123+/−,CD25−,CD99low/−) (p = 0.0005) and mononuclear cells (MNCs) (p < 0.0001). This was associated with significantly increased CD99 mean fluorescence intensity in LPCs. Significantly higher FLT3-ITDmut burden was also observed in LPCs of AML patients with a small FLT3-ITDmut clones at diagnosis. On the contrary, the mutation burden of other myeloid genes was similar in MNCs, highly purified LPCs and/or CD34+ progenitors. Treatment with an anti-CD99 mAb was cytotoxic on LPCs in two patients, whereas there was no effect on CD34+ cells from healthy donors. Our study shows that FLT3-ITD mutations occur early in LPCs, which represent the leukemic reservoir. CD99 may represent a new therapeutic target in FLT3-ITDmut AML. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results